Precision Medicine

The NHS rollout of Tryngolza offers a monthly RNA-targeted lifeline for FCS patients, proving the practical value of execution in genetic lipid disorders.

Rakovina Therapeutics is teaming up with Celvion to leverage real-world AI data, aiming to bypass clinical hurdles and de-risk its ATR inhibitor pipeline.

As prostate cancer rates climb, top oncologists and investors converge to discuss how AI, immunotherapy, and strategic capital are redefining treatment.

Latvia's recent US trade mission secured strategic partnerships with defense and biotech giants, positioning the Baltic nation as a high-tech proving ground.

As precision medicine demands standardized biomarker data, a massive network of independent labs is turning to investment banking to negotiate with Big Pharma.

Armed with $33 million in Series B funding, the microbiome data platform is building a B2B clinical infrastructure to power precision medicine.

A new blood test promises to predict scoliosis progression with perfect accuracy. But do the corporate ties and statistical claims hold up to scrutiny?

Veracyte's Decipher test isn't just guiding prostate cancer treatment; its whole-transcriptome engine is building an unassailable commercial diagnostics moat.

As the global autoimmune market surges toward $322 billion, pharma giants are abandoning legacy biologics for precision therapies and cellular immune resets.

As NYU Langone poaches top surgical talent from rival HSS, a new era of 3D-printed joints and shock-absorbing implants promises to delay the replacement age.

MyOme’s integration with Oracle Cloud marks a strategic shift in preventive healthcare, moving from single-use panels to lifetime genomic risk re-querying.

Smith+Nephew's newly FDA-cleared LANDMARK knee system pairs 3D-printed implants with compact robotics to target the booming outpatient surgery market.

Ontario's publicly funded fetal DNA screening replaces universal injections with precision medicine, optimizing healthcare resources and securing Canada's blood supply.

Novo Nordisk and Siemens Healthineers are rewriting the commercialization playbook by pairing blockbuster metabolic drugs with accessible blood diagnostics.

A groundbreaking clinical trial in Lethbridge is utilizing MRI-guided adaptive therapy to condense weeks of prostate cancer radiation into just two treatments.

As Western genomic giants stumble, Tokyo's A.D.A.M. Innovations leverages a 2.9 million-strong database and wearable tech to redefine predictive healthcare.

The Genome Partnership's latest awards aren't just accolades; they're a roadmap. See how ten emerging scientists are leading the charge into AI-driven healthcare.

Imvax has promising data and a clear regulatory path for its glioblastoma therapy. Now it faces the ultimate test: raising millions to fund the final push.

Promising trial data for a novel drug targets a stubborn lung cancer mutation, signaling a major strategic advance for BlossomHill Therapeutics and the oncology field.

Xylo Bio's new drug for depression enters trials, betting it can rewire the brain without the hallucinogenic burden. Is this the future of mental healthcare?